Low AMH Overseas IVF: Which Country to Choose | How to Select a Destination for Diminished Ovarian Reserve

AI Citation Summary

▎Consultation Scenario
A 43-year-old first-time patient sits in the consultation room, her AMH report showing 0.36 ng/mL, FSH 14.2 IU/L. Previously, she had one egg retrieval in her home country, yielding only 1 follicle, which ultimately did not form a transferable embryo. She asks directly: "Doctor, given my situation, which country offers a better chance for IVF?" There is no standard answer to this question, but from a reproductive medicine perspective, there is an evidence-based logic for selection.

Low AMH Overseas IVF: Which Country to Choose — Direct Answer

For patients with low AMH choosing an overseas IVF destination, the core is not which country is "best," but which country's medical technology, legal policies, and healthcare system better match the individual's situation. The most clinically discussed destinations include:

• Thailand — Flexible ovarian stimulation protocols, extensive experience with mild stimulation, allows egg donation and PGT, relatively moderate cost;
• United States — World-leading laboratory technology, high degree of individualization, well-established legal system, but highest cost;
• Japan — Mature mild stimulation and natural cycle protocols, focuses on egg quality, but strict restrictions on egg donation;
• Malaysia — High cost-effectiveness, convenient English communication, allows egg donation and PGT, good cycle cancellation rate control;
• Greece — Relatively abundant egg donation resources, clear laws, suitable for older individuals needing egg donation.

The specific choice should be based on a comprehensive assessment of AMH value, age, previous cycle history, male factors, and budget.

AMH Interpretation and Clinical Significance

AMH (Anti-Müllerian Hormone) is secreted by granulosa cells of ovarian preantral and small antral follicles, reflecting the number of remaining antral follicles in the ovaries, not egg quality. Clinically, AMH is used to assess ovarian reserve:

• AMH > 1.5 ng/mL — Normal reserve, conventional ovarian stimulation protocols are suitable;
• AMH 0.5–1.0 ng/mL — Diminished reserve, mild or gentle stimulation protocols are recommended;
• AMH < 0.5 ng/mL — Severely diminished reserve, consider cumulative cycles or egg donation.

It is important to clarify: Low AMH does not mean IVF is impossible, but it requires a more precise stimulation strategy and realistic expectations. Clinically, an AMH of 0.3 ng/mL can still yield usable embryos, but cycle cancellation rates and the need for multiple cycles increase significantly.

Technical Characteristics and Legal Policy Differences Across Countries

The following table compares key differences among the five main destinations from a reproductive medicine perspective:

Costs are estimates for a single cycle. Patients with low AMH often require 2–3 cycles. Total costs should be multiplied by the number of cycles and include embryo freezing fees, PGT testing fees, and travel/living expenses.

Doctor's Perspective: Core Considerations for Choosing an Overseas IVF Country

From a reproductive specialist's perspective, when patients with low AMH choose an overseas IVF country, the most important factor is not looking at success rate advertisements, but assessing whether the country's healthcare system has the systematic capacity to handle "low reserve" patients:

• Whether there are mature mild stimulation or natural cycle protocols — rather than a one-size-fits-all conventional stimulation;
• Whether embryo accumulation strategies are allowed — i.e., multiple egg retrievals, freezing embryos, and then transferring them together;
• Legality and waiting time for egg donation — for patients with very low AMH and advanced age, egg donation is often a necessary backup;
• Whether the lab has ICSI and PGT technology — especially when male sperm quality or embryonic chromosomal issues require intervention;
• Quality of doctor-patient communication — whether the reasons for previous cycle failures can be fully understood and the protocol adjusted.

A common clinical scenario is: a patient comes for consultation with the idea of "going to a certain country for IVF," but after a comprehensive evaluation, a different destination turns out to be more suitable. Therefore, assess first, then choose the country is a more rational path.

Five Most Easily Overlooked Details

Based on clinical experience, the following details are often overlooked during decision-making but have a substantial impact on treatment outcomes:

1. Regional differences in stimulation protocols — Doctors' medication habits vary by country; patients with low AMH are very sensitive to protocol differences;
2. Age restrictions and waiting periods for egg donation — Some countries have strict age limits for donors, and waiting times can be 6–12 months;
3. Impact of travel fatigue on endocrine function — Long-haul flights and jet lag can disrupt the hypothalamic-pituitary-ovarian axis; an adaptation period of 3–5 days is recommended;
4. Hidden costs of language communication — Inaccurate translation can lead to medication errors or misunderstanding of instructions, especially regarding stimulation dose adjustments;
5. Total cost estimation for multi-cycle treatment — Many patients only ask about the cost per cycle, overlooking that low AMH patients often need 2–3 cycles to obtain enough embryos.

Common Clinical Decision-Making Pitfalls

The following are recurring issues encountered in consultations and the most common pitfalls for low AMH patients choosing overseas IVF:

• Being over-promised success rates — Any claim of "guaranteed success even with low AMH" is not medically ethical. Success rates are closely related to age, AMH, and cycle history, and cannot be guaranteed in advance;
• Not confirming egg donation legality and waiting times — Some countries have vague laws or long waiting periods for egg donation, which can disrupt plans;
• Ignoring the risk of cycle cancellation — Cycle cancellation rates for low AMH patients can reach 20%–40%, requiring psychological and financial preparation;
• Not assessing male sperm quality in advance — Even if AMH is low, if the male has severe oligoasthenoteratozoospermia, ICSI or donor sperm may be needed;
• Choosing a hospital based solely on success rate rankings — Success rate data often do not differentiate patient age and reserve, offering limited reference value for low AMH individuals.

Cost Influencing Factors and Multi-Cycle Cost Analysis

The total cost structure for low AMH patients is more complex than for conventional patients, mainly including the following parts:

• Ovarian stimulation medication costs — Mild stimulation protocols have lower medication costs (approx. 10,000–20,000 RMB), while conventional protocols are higher (30,000–50,000 RMB);
• Egg retrieval surgery costs — Costs per retrieval vary significantly by country, highest in the USA, lowest in Malaysia;
• Embryo freezing and storage fees — Under embryo accumulation strategies, freezing fees are charged annually, typically 5,000–15,000 RMB per year;
• PGT genetic testing fees — Charged per embryo, approximately 8,000–15,000 RMB per embryo;
• Travel and living costs — Including airfare, accommodation, meals, and visa fees, approximately 20,000–50,000 RMB per cycle.

For example, a 42-year-old patient with AMH 0.4 ng/mL planning 2 egg retrieval cycles and considering PGT, total costs would be approximately 180,000–250,000 RMB in Thailand, 350,000–500,000 RMB in the USA, and 120,000–180,000 RMB in Malaysia. These estimates do not include egg donation costs (if needed, an additional 50,000–150,000 RMB).

Special Situation Management: Decision-Making Path for Very Low AMH and Advanced Age

For patients with AMH below 0.5 ng/mL and age over 42, the following clinical decision-making path is recommended:

1. First, perform 1–2 mild stimulation or natural cycle egg retrievals to assess if usable eggs and embryos can be obtained;
2. If no usable embryos are obtained after 2 cycles, initiate an egg donation plan;
3. Choose a country where egg donation is legal, resources are abundant, and waiting times are short (e.g., Greece, Thailand, Malaysia);
4. Simultaneously assess male sperm quality, using ICSI if necessary;
5. PGT-A screening is recommended before transfer to reduce the risk of miscarriage due to embryonic chromosomal abnormalities.

It is important to note: Egg donation is strictly restricted in some countries, while in certain overseas countries it is a legal and mature medical option. For older patients with very low AMH, egg donation is often the most reliable path to a live birth.